Variagenics buys abnormal deoxyribonucleic acid (DNA) cleaving technology:
This article was originally published in Clinica
Privately-held Variagenics has acquired what the company describes as "fundamental technologies for the rapid identification of gene sequence variations", by purchasing almost all the assets of Avitech Diagnostics for an undisclosed sum. The technologies include the trademarked Variance Imaging technique for detecting all types of DNA mismatches based on identifying cleavage points. US company Variagenics says it will continue Avitech's alliance with Amersham Pharmacia Biotech which has the worldwide rights to commercialise Enzymic Mutation Detection, upon which Variance Imaging is based.